OrbiMed Advisors OSCR Position
Exited3-Fund ConvergenceOrbiMed Advisors exited their position in Oscar Health, Inc. (OSCR) in Q4 2024, after holding the stock for 2 quarters.
The position was first reported in Q3 2024 and has been tracked across 2 quarterly 13F filings.
OSCR is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 11.1% of float with 3.9 days to cover, indicating significant bearish positioning against the stock.
About Oscar Health, Inc.
Oscar Health, Inc. provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a technology driven platform designed to help providers and payor clients to engage with members and patients. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.
Full company profile →Short Interest
11.1%
3.9 days to cover
OrbiMed Advisors OSCR Position History
Frequently Asked Questions
Does OrbiMed Advisors own OSCR?
No. OrbiMed Advisors exited their position in Oscar Health, Inc. (OSCR) in Q4 2024. They previously held the stock for 2 quarters.
How many hedge funds own OSCR?
3 specialist biotech hedge funds currently hold OSCR, including Deerfield Management, Rock Springs Capital, Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy OSCR?
OrbiMed Advisors's position in OSCR was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's OSCR position increasing or decreasing?
OrbiMed Advisors completely exited their OSCR position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
OSCRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →